Moreover, the encouraging results from METTL3 inhibitors, several of which are currently in early clinical development, along with evidence that combining METTL3 inhibitors with PD-L1 blockade enhances antitumor immune efficacy, offer new avenues for cancer treatment [34]. Here, CD274 is linked to cancer.